Diabetic Kidney Disease (DKD): Latest Recommendations (2025-2026)

1. Diagnosis & Monitoring

• Defined by persistent albuminuria (urine ACR ≥30 mg/g) and/or reduced eGFR (<60 mL/min/1.73 m²) for >3 months in a person with diabetes, after excluding other causes.
• HbA1c remains the recommended biomarker to monitor glycemic control in DKD (KDIGO 2026, Recommendation 2.1.1).
• Monitor urine ACR, serum creatinine/eGFR, and potassium at regular intervals (frequency increases with higher CKD stage and albuminuria category).
• Nephrology referral when eGFR <30 mL/min/1.73 m², ACR >300 mg/g, unexplained hematuria, or rapidly declining renal function. - Harrison's Principles of Internal Medicine 22E, p. 3269

2. Glycemic Targets

• Individualized HbA1c target of <6.5% to <8.0% in people with diabetes and CKD not treated with dialysis (KDIGO 2026 Diabetes & CKD Guideline, Recommendation 2.2.1 - Level 1C).
• A target of ≤7% is appropriate for most patients; looser targets (≤8%) are acceptable in patients with significant comorbidities, hypoglycemia risk, or limited life expectancy. - Goldman-Cecil Medicine, p. 1276
• Tight control significantly reduces the incidence of nephropathy in type 1 DM and slows progression of microvascular complications in type 2 DM, though it does not fully eliminate risk.

3. Blood Pressure Control

• Target <130/80 mmHg for individuals with diabetes and DKD. - Harrison's Principles of Internal Medicine 22E, p. 3268
• If BP >150/90 mmHg: start with two antihypertensive agents.
• Lifestyle modifications are part of treatment: weight loss, DASH-style diet, sodium restriction (<2 g/day), exercise, and smoking cessation.

4. The Four Pharmacological Pillars (2026 Guideline Consensus)

Pillar 1: RAS Inhibition (ACE inhibitor or ARB)

• Indicated in all patients with DKD and albuminuria (moderately-to-severely increased, A2/A3, stages G1-G4) - KDIGO 2026 Strong Recommendation (1B).
• ACEi and ARBs are equivalent; ARBs may be preferred if ACEi-associated cough or angioedema develops.
• Titrate to maximum tolerated dose; a creatinine rise up to 30% from baseline is acceptable.
• Do not combine ACEi + ARB (dual blockade shown to increase adverse events).
• Direct renin inhibitors (aliskiren) are contraindicated in patients with DM and moderate/severe CKD taking ACEi or ARBs (ALTITUDE trial). - NKF Primer on Kidney Diseases 8e, p. 301

Pillar 2: SGLT2 Inhibitors (first-line for most patients)

• KDIGO 2026 strong recommendation (1A): Start SGLT2 inhibitor in all patients with T2D + CKD with eGFR ≥20 mL/min/1.73 m², regardless of albuminuria level.
• Benefit is independent of glycemic control - reduces intraglomerular pressure via osmotic/tubuloglomerular feedback and reduces cardiovascular events.
• Continue SGLT2i even if eGFR falls below 20 mL/min/1.73 m² after initiation (unless intolerance or dialysis begins) - do not stop for an eGFR dip alone.
• Withhold during prolonged fasting, surgery, or critical illness (euglycemic DKA risk).
• Agents with proven benefit: canagliflozin (CREDENCE), dapagliflozin (DAPA-CKD), empagliflozin (EMPA-KIDNEY). - Harrison's 22E, p. 3269; Comprehensive Clinical Nephrology 7e

Pillar 3: Nonsteroidal MRA - Finerenone

• Finerenone (nonsteroidal, selective MRA) is now guideline-recommended for T2D with DKD - reduces kidney failure progression and cardiovascular events.
  • FIDELIO-DKD: 18% reduction in the composite kidney endpoint (kidney failure, sustained eGFR decline ≥40%, kidney death).
  • FIGARO-DKD: 14% reduction in the cardiovascular composite.
  • Combined FIDELIO/FIGARO analysis (>13,000 patients): HR 0.86 (95% CI 0.78-0.95) for CV composite. - NKF Primer 8e, p. 301; KDIGO 2026 Draft
• Advantages over steroidal MRAs (spironolactone, eplerenone): lower rates of hyperkalemia and no anti-androgenic side effects.
• 2026 ADA new recommendation (11.9): Simultaneous initiation of SGLT2i and nsMRA can be considered for T2D patients with urine ACR ≥100 mg/g and eGFR 30-90 mL/min/1.73 m², already on a RAS inhibitor.

Pillar 4: GLP-1 Receptor Agonists / GLP-1-Based Therapies

• Recommended as the next priority after SGLT2i and RASi, given established cardiovascular and kidney benefits.
• Semaglutide (FLOW trial): Improved kidney outcomes and reduced CV death in T2D with CKD.
• Indicated especially when:
  • Residual albuminuria persists despite RASi + SGLT2i (residual risk is a reasonable trigger)
  • SGLT2i cannot be used or is insufficient for glycemic goals
  • Additional CV risk reduction is needed
• 2026 ADA new recommendation (11.11a): GLP-1-based therapy can be continued or initiated even in patients on dialysis to reduce cardiovascular risk. - KDIGO 2026 Public Review Draft; Harrison's 22E, p. 3269

5. Glucose-Lowering Agent Hierarchy in DKD (KDIGO 2026 Framework)

6. Lipid Management

• Statin therapy is recommended to reduce atherosclerotic cardiovascular disease risk in all DKD patients. - NKF Primer 8e; KDIGO 2026
• Target LDL-C per individual risk (high-intensity statin for most).
• The SHARP trial established safety and efficacy of lipid lowering in CKD.

7. Dietary & Lifestyle Recommendations

• Protein intake: 0.8 g/kg/day in individuals with DKD (ADA/Harrison's recommendation). Lower protein intake may reduce hyperfiltration and slow progression; restriction to 0.6-0.8 g/kg is appropriate in stage III-IV.
• Sodium restriction: <2 g/day.
• Weight loss and regular exercise enhance the effects of pharmacotherapy.
• Annual diabetic eye examination to detect concomitant retinopathy.

8. Special Situations

Key Guideline Sources

• KDIGO 2026 Diabetes & CKD Guideline Update (Public Review Draft, March 2026 - literature searched through July 2025)
• 2026 ADA Standards of Care in Diabetes (published December 2025)
• Harrison's Principles of Internal Medicine 22E (2025), Chapter 417
• Goldman-Cecil Medicine, Chapter 109
• NKF Primer on Kidney Diseases, 8th Edition
• Comprehensive Clinical Nephrology, 7th Edition